These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 25132750)
41. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366 [TBL] [Abstract][Full Text] [Related]
42. Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? Leow AH; Azmi AN; Loke MF; Vadivelu J; Graham DY; Goh KL J Dig Dis; 2018 Nov; 19(11):674-677. PubMed ID: 30307122 [TBL] [Abstract][Full Text] [Related]
43. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221 [TBL] [Abstract][Full Text] [Related]
45. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. Fallone CA; Moss SF; Malfertheiner P Gastroenterology; 2019 Jul; 157(1):44-53. PubMed ID: 30998990 [TBL] [Abstract][Full Text] [Related]
46. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG; Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798 [TBL] [Abstract][Full Text] [Related]
47. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial. Pan J; Shi Z; Lin D; Yang N; Meng F; Lin L; Jin Z; Zhou Q; Wu J; Zhang J; Li Y Front Med; 2020 Feb; 14(1):43-50. PubMed ID: 31907860 [TBL] [Abstract][Full Text] [Related]
48. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Wu DC; Hsu PI; Wu JY; Opekun AR; Kuo CH; Wu IC; Wang SS; Chen A; Hung WC; Graham DY Clin Gastroenterol Hepatol; 2010 Jan; 8(1):36-41.e1. PubMed ID: 19804842 [TBL] [Abstract][Full Text] [Related]
49. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. Su J; Zhou X; Chen H; Hao B; Zhang W; Zhang G Medicine (Baltimore); 2017 Feb; 96(7):e5859. PubMed ID: 28207505 [TBL] [Abstract][Full Text] [Related]
50. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Georgopoulos S; Papastergiou V Expert Opin Pharmacother; 2021 Apr; 22(6):729-741. PubMed ID: 33131337 [No Abstract] [Full Text] [Related]
52. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Lim JH; Lee DH; Choi C; Lee ST; Kim N; Jeong SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Jo HJ; Jang ES; Song Is; Jung HC Helicobacter; 2013 Jun; 18(3):180-6. PubMed ID: 23305083 [TBL] [Abstract][Full Text] [Related]
53. [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection]. Campillo A; Amorena E; Ostiz M; Kutz M; LaIglesia M Gastroenterol Hepatol; 2016 Nov; 39(9):584-589. PubMed ID: 27084668 [TBL] [Abstract][Full Text] [Related]
55. Pharmacological therapy used in the elimination of Helicobacter pylori infection: a review. Dos Santos AA; Carvalho AA World J Gastroenterol; 2015 Jan; 21(1):139-54. PubMed ID: 25574087 [TBL] [Abstract][Full Text] [Related]
56. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients. Yang X; Tan P; Song L; Lu Z Am J Ther; 2016; 23(6):e1436-e1441. PubMed ID: 25923229 [TBL] [Abstract][Full Text] [Related]
57. Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance. Valle Muñoz J; Muñoz Gómez P; Sierra Bernal C; de Andrés E; Gómez Hernando C; Gómez Rodríguez R Rev Esp Enferm Dig; 2019 Sep; 111(9):655-661. PubMed ID: 31345044 [TBL] [Abstract][Full Text] [Related]
58. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Long X; Chen Q; Yu L; Liang X; Liu W; Lu H Helicobacter; 2018 Jun; 23(3):e12485. PubMed ID: 29696736 [TBL] [Abstract][Full Text] [Related]
59. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection. Zheng Q; Pan Y; Zhang L; Xiao SD Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231 [TBL] [Abstract][Full Text] [Related]
60. [Efficacy of bismuth containing quadruple therapies on Helicobacter pylori eradication in patients with history of antibiotic treatment]. Tang D; Yuan L; Yue C; Cai T; Yao Y; Wang F Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 43(7):772-778. PubMed ID: 30124214 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]